Tivozanib is being evaluated in combination with the PD-1 inhibitor nivolumab versus tivozanib monotherapy in patients with advanced RCC who received prior IO therapy in the phase III TiNivo-2 study (NCT04987203).27 The gene discussed is PDCD1; the disease is renal cell carcinoma.